Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00954655|
Recruitment Status : Recruiting
First Posted : August 7, 2009
Last Update Posted : August 8, 2017
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at tumor samples in patients undergoing treatment for gastrointestinal stromal tumors on clinical trial ACOSOG-Z9001.
|Condition or disease||Intervention/treatment|
|Gastrointestinal Stromal Tumor||Genetic: mutation analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis|
- To examine polymorphisms in selected genes involved in the detoxifying/metabolizing and DNA repair pathways in relation to specific mutations and types of mutation in the c-kit gene in tumor tissue from patients with gastrointestinal tumors (GIST) undergoing treatment on clinical trial ACOSOG-Z9001.
- To examine approximately 758 polymorphisms among candidate genes involved in detoxification/metabolism, cell cycle control, and DNA damage/repair in relation to specific mutations and types of mutation in the c-kit gene in tumor tissue from GIST patients for hypothesis generation. (exploratory)
- To conduct an exploratory analysis of the polymorphism distribution in these patients. (exploratory)
- To examine the association between the above polymorphisms and major toxicity (Grade 3/4) of adjuvant imatinib mesylate. (exploratory)
OUTLINE: Tumor samples are used for polymorphism and mutation analysis.
|Study Type :||Observational|
|Estimated Enrollment :||374 participants|
|Official Title:||Genetic Risk Factors for Gastrointestinal Stromal Tumors (GIST)|
|Study Start Date :||December 2008|
|Estimated Primary Completion Date :||January 2100|
Tumor samples are used for polymorphism and mutation analysis.
|Genetic: mutation analysis Genetic: polymorphism analysis Other: laboratory biomarker analysis|
- response [ Time Frame: Up to 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00954655
|Contact: Lawrence Engel, MDemail@example.com|
|United States, New York|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10021|
|Contact: Lawrence Engel, MD firstname.lastname@example.org|
|Study Chair:||Lawrence Engel, MD||Memorial Sloan Kettering Cancer Center|